Hudson Bay Capital Management
RIGL icon

Hudson Bay Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Hudson Bay Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,500
Closed -$113K – 972
2022
Q4 		$113K Hold
7,500
– – ﹤0.01% 759
2022
Q3 		$89K Hold
7,500
– – ﹤0.01% 944
2022
Q2 		$85K Buy
7,500
+5,520
+279% +$111K ﹤0.01% 1036
2022
Q1 		$59K Buy
+1,980
New +$53.6K ﹤0.01% 995
2018
Q1 		– Sell
-10,000
Closed -$388K – 845
2017
Q4 		$388K Buy
+10,000
New +$381K 0.01% 444

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hudson Bay Capital Management's RIGL Position: Q4 2022 in Review

Hudson Bay Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2022, closing a stake of 330,000 shares — an estimated $3.03M sold.

Hudson Bay Capital Management first reported a position in RIGL in Q1 2017 and held it in 23 quarters. The position peaked at $11.4M in Q1 2022. 118 funds tracked by Wall St. Rank hold RIGL as of Q4 2022.

  • Hudson Bay Capital Management reported no remaining Rigel Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Hudson Bay Capital Management sold 330,000 Rigel Pharmaceuticals shares in Q4 2022, an estimated $3.03M.
  • Hudson Bay Capital Management first reported a position in Rigel Pharmaceuticals in Q1 2017 and held it in 23 quarters.
  • Hudson Bay Capital Management's Rigel Pharmaceuticals position peaked at $11.4M in Q1 2022.
  • 118 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2022.

Based on Hudson Bay Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.